Peptides for Anti-Aging and Longevity: What the Evidence Shows

The short answer

"Anti-aging peptide" is a marketing category, not a medical one. No peptide has been tested in a trial long enough, or large enough, to show that it slows ageing or extends life in people. What the literature does hold falls into three groups: drugs approved for a specific disease, such as tesamorelin for abdominal fat in HIV and elamipretide for Barth syndrome; human studies that measured a hormone, a blood marker or body composition; and animal and cell studies, which are where nearly all of the longevity claims come from.

The closest test of the idea behind many of these products is growth hormone itself. A systematic review of randomised trials in healthy people with an average age of 69 found that growth hormone reduced fat mass by 2.1 kg and increased lean mass by 2.1 kg, with no change in weight, bone density or most blood lipids. People on it had more soft-tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement, and were somewhat more likely to develop diabetes or impaired fasting glucose. The authors concluded that growth hormone cannot be recommended as an anti-ageing therapy.¹ Every peptide that works by raising growth hormone inherits that question.

Growth hormone secretagogues: effects on hormones, not on ageing

These compounds make the pituitary release more of its own growth hormone. They do raise growth hormone and IGF-1; none has been tested for ageing.

CJC-1295. In its two published trials in healthy adults, a single injection raised growth hormone and IGF-1 for days.² FDA reports having identified serious adverse events associated with it, including increased heart rate and a systemic vasodilatory reaction, and notes that clinical data are limited.³ There is no trial of CJC-1295 in older adults, and none of the popular combination with ipamorelin.

Ipamorelin. Its one controlled human trial was in bowel-surgery patients with postoperative ileus, not ageing.⁴

Sermorelin. FDA approved it as Geref in 1990 and 1997; both applications are listed as discontinued,⁵ and FDA later determined the product was not withdrawn for reasons of safety or effectiveness.⁶ Its approvals were for children, not for ageing adults.

Tesamorelin. The one approved drug in the group, for excess abdominal fat in adults with HIV. In two phase 3 trials of 806 patients it cut visceral fat by 15.4% more than placebo at 26 weeks, without changing fat under the skin,⁷ and people switched to placebo regained the visceral fat.⁸ Its label warns of fluid retention, joint pain, carpal tunnel syndrome and glucose intolerance, with HbA_1c reaching 6.5% or more in 5% of treated patients against 1% on placebo.⁹

MK-677 (ibutamoren). An oral ghrelin mimetic, not a peptide. In a two-year trial in 65 healthy adults aged 60 to 81 it added 2.7 kg of body weight against 0.8 kg on placebo, increased limb fat, raised fasting glucose and reduced insulin sensitivity,¹⁰ and its trial in older adults recovering from hip fracture was stopped early over a signal of congestive heart failure.¹¹

Mitochondrial peptides: one approval, in a rare disease

Elamipretide (SS-31). FDA granted it accelerated approval on September 19, 2025 as Forzinity, to improve muscle strength in people with Barth syndrome, an ultra-rare inherited disorder of the mitochondrial lipid cardiolipin.¹² The approval rested on a small crossover trial that missed its primary endpoint, its open-label extension and a natural-history comparison.¹³ Its larger trials went the other way: in 218 adults with primary mitochondrial myopathy, 24 weeks of daily injections did not improve the six-minute walk or fatigue scores against placebo,¹⁴ and in 71 people with heart failure with reduced ejection fraction, 28 days did not change left-ventricular volumes.¹⁵ Nobody has tested it for ageing.

MOTS-c. A 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015. In mice it prevented age-related and diet-induced insulin resistance and obesity.¹⁶ In people it has only been measured: a genetic variant that changes one of its amino acids was linked to type 2 diabetes in men across 27,527 people.¹⁷ FDA's Pharmacy Compounding Advisory Committee reviewed it with BPC-157 and TB-500 in July 2026.¹⁸

Humanin. The first peptide found to be encoded in mitochondrial DNA and the founder of the mitochondrial-derived peptide family.¹⁹ Its evidence is laboratory and animal work plus measurements in people; it has never been given to anyone as a treatment.

Epithalon and the telomere claim

Epithalon (epitalon) is a four-amino-acid peptide from the laboratory of Vladimir Khavinson in Russia. In cultures of human fetal fibroblasts it switched on telomerase and lengthened telomeres.²⁰ In a lifetime study in mice, it did not change average lifespan, body weight or food intake; the longest-lived tenth lived 13.3% longer and leukaemia was less frequent, while total tumour incidence did not change.²¹ A 2025 review of its in vitro, animal and computer-modelling literature is candid that its mechanisms remain uncertain.²² It has barely been tested in people, most of the work comes from the group that developed it, and it was among the substances FDA's compounding committee reviewed in July 2026.¹⁸

NAD+: a coenzyme, not a peptide

NAD+ is often sold alongside peptides, but it is a coenzyme. A 2026 systematic review found 33 human trials: oral precursors such as nicotinamide riboside and NMN raised NAD-related metabolites and were well tolerated, but their effects on function, metabolism and blood vessels were inconsistent and often absent, and no outcome trial has tested intravenous or intramuscular NAD+ itself for ageing or wellness.²³ A clinic's review of intravenous NAD+ found it caused gastrointestinal symptoms, a faster heart rate and chest pressure during the drip, stretching infusions to 97 minutes against 37 for nicotinamide riboside.²⁴

GHK-Cu and cosmetic peptides: skin, not lifespan

Copper peptide GHK-Cu and the cosmetic peptides in creams target the appearance of skin, not biological ageing. The evidence for them is thinner than their marketing. In a small randomised trial after laser resurfacing, GHK-Cu did not speed the fading of redness or change wrinkles or skin quality as measured by computer analysis and blinded evaluators, although patients rated their skin higher.²⁵ A 2025 review found cell studies supporting GHK as an anti-wrinkle ingredient but a surprising absence of clinical studies of it.²⁶ Injecting GHK-Cu has no published trial at all.

Thymosin alpha-1

Thymosin alpha-1 is sold in some anti-ageing protocols as an immune booster. Its largest trial tested it in 1,106 adults with sepsis: 28-day mortality was 23.4% on thymosin alpha-1 and 24.1% on placebo, and no secondary outcome differed.²⁷ It has not been tested as an anti-ageing treatment.

What this means in practice

The approved drugs here are prescribed for their approved uses, by doctors who can monitor them. For everything else, the honest description is untested: the absence of human data is not evidence of safety, and a blood test for IGF-1 measures a hormone, not ageing. Our evidence grades say how strong the human evidence is for each compound, and the regulatory tracker follows the compounding status of BPC-157, TB-500, epithalon and MOTS-c after the July 2026 advisory committee meeting, as of September 30, 2026. Several growth hormone secretagogues are prohibited in sport; see the legal status guide.

Frequently asked questions

Is there a peptide that slows ageing?

No peptide has been shown to slow ageing or extend lifespan in people. The human evidence covers specific diseases, hormones or body composition; the longevity claims come from cell and animal studies.

Is CJC-1295 with ipamorelin an anti-ageing treatment?

Neither has been tested for ageing, and the combination has no published human trial. CJC-1295 raised growth hormone and IGF-1 in healthy adults, ipamorelin's human trial was in postoperative ileus, and FDA has reported serious adverse events with CJC-1295.

Is elamipretide (SS-31) approved?

Yes, since September 19, 2025, but only for Barth syndrome, a rare genetic disease, under accelerated approval. Its phase 3 trial in primary mitochondrial myopathy and its phase 2 trial in heart failure were negative.

Does epithalon lengthen telomeres in people?

That has not been shown. It switched on telomerase in cell cultures, and in mice it did not change average lifespan, though the longest-lived tenth lived 13.3% longer. Most of the work comes from the group that developed it.

Does growth hormone reverse ageing?

Not in the trials. In a systematic review of randomised trials in healthy older people, growth hormone reduced fat by about 2 kg and added about 2 kg of lean mass with no change in weight, and caused more swelling, joint pain, carpal tunnel syndrome and breast enlargement.

Related on Grey Peptides

• Peptide side effects
• MK-677 complete guide
• CJC-1295 complete guide
• SS-31 (elamipretide) encyclopedia entry
• Epithalon encyclopedia entry
• MOTS-c encyclopedia entry

Sources

1. Liu, H. et al. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med, 146(2), 104-15. PMID: 17227934 · doi:10.7326/0003-4819-146-2-200701160-00005
2. Teichman, S. L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
3. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks: CJC-1295 (serious adverse events including increased heart rate and systemic vasodilatory reaction; clinical data limited). Content current as of April 22, 2026; read September 30, 2026. FDA
4. Beck, D. E. et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis, 29(12), 1527-34. PMID: 25331030
5. U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate), NDA 019863 (0.05 mg ampoule, approved December 28, 1990) and NDA 020443 (0.5 mg and 1 mg vials, approved September 26, 1997), EMD Serono; both discontinued (read September 28, 2026).
6. U.S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register 78:14096, March 4, 2013 (Docket FDA-2012-P-1071). Federal Register notice
7. Falutz, J. et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab, 95(9), 4291-304. PMID: 20554713 · doi:10.1210/jc.2010-0490
8. Falutz, J. et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719-28. PMID: 18690162 · doi:10.1097/QAD.0b013e32830a5058
9. Theratechnologies Inc. EGRIFTA SV (tesamorelin) for injection, US prescribing information: section 5 (fluid retention with edema, arthralgia and carpal tunnel syndrome; glucose intolerance, HbA1c 6.5% or higher in 5% vs 1%; hypersensitivity; injection site reactions 25% vs 14% over 26 weeks; evaluate glucose before and during therapy). DailyMed version of July 31, 2026, read September 30, 2026.
10. Nass, R. et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med, 149(9), 601-11. PMID: 18981485
11. Adunsky, A. et al. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr, 53(2), 183-9. PMID: 21067829
12. Shirley, M. (2026). Elamipretide: First Approval. Drugs, 86(3), 377-383. PMID: 41335372 · doi:10.1007/s40265-025-02269-8
13. Thompson, W. R. et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med, 23(3), 471-478. PMID: 33077895 · doi:10.1038/s41436-020-01006-8
14. Karaa, A. et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology, 101(3), e238-e252. PMID: 37268435 · doi:10.1212/WNL.0000000000207402
15. Butler, J. et al. (2020). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail, 26(5), 429-437. PMID: 32068002 · doi:10.1016/j.cardfail.2020.02.001
16. Lee, C. et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 21(3), 443-54. PMID: 25738459 · doi:10.1016/j.cmet.2015.02.009
17. Zempo, H. et al. (2021). A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY), 13(2), 1692-1717. PMID: 33468709 · doi:10.18632/aging.202529
18. US Food and Drug Administration (2026). Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: briefing documents for BPC-157, TB-500, epitalon and four other bulk drug substances. FDA
19. Lee, C. et al. (2013). Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab, 24(5), 222-8. PMID: 23402768 · doi:10.1016/j.tem.2013.01.005
20. Khavinson, V. K. et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590-592. PMID: 12937682
21. Anisimov, V. N. et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193-202. PMID: 14501183 · doi:10.1023/a:1025114230714
22. Araj, S. K. et al. (2025). Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci, 26(6). PMID: 40141333 · doi:10.3390/ijms26062691
23. Gallagher, C. & Emmanuel, O. O. (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev, 116, 103057. PMID: 41655607 · doi:10.1016/j.arr.2026.103057
24. Reyna, K. et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging, 7, 1652582. PMID: 41704678 · doi:10.3389/fragi.2026.1652582
25. Miller, T. R. et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171 · doi:10.1001/archfaci.8.4.252
26. Mortazavi, S. M. et al. (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 15, 30071. PMID: 39963574 · doi:10.34172/bi.30071
27. Wu, J. et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583. PMID: 39814420 · doi:10.1136/bmj-2024-082583

This article summarises trials, reviews, labels and regulatory records. It is not medical advice, and the lack of a harm on this page does not make an untested compound safe.